# Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07306624/  
OnCo record `nct07306624` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by STCube, Inc., now recruiting.

## Summary

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07306624 by STCube, Inc., with 62 participants planned, started 2026-01-10 and due to reach its primary completion in 2027-08-31. Interventions recorded: Nelmastobart and Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07306624
- Phase: 2
- Setting: A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination With Docetaxel in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
- Sponsor: STCube, Inc.
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT07306624: https://clinicaltrials.gov/study/NCT07306624

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [STCube](https://onco.cc/companies/stcube/)

---
JSON: https://onco.cc/api/v1/entities/nct07306624.json